NasdaqGS:CTMXBiotechs
Will CytomX Therapeutics' (CTMX) CX-801 Data Deepen Confidence in Its Immunotherapy Platform?
CytomX Therapeutics announced it will present initial translational data from its ongoing Phase 1 study of CX-801 in advanced melanoma at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, MD.
This upcoming clinical update provides stakeholders with a key opportunity to assess the potential of CytomX's immunotherapy pipeline, possibly shaping future expectations around its development progress and clinical...